Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

ADMIRAL results solidify gilteritinib as new standard for FLT3-mutated AML

Key clinical point: For patients with FLT3-mutated, relapsed or refractory acute myeloid leukemia (AML), gilteritinib offers better median overall survival than salvage chemotherapy.

Major finding: Patients treated with gilteritinib had a median OS of 9.3 months, compared with 5.6 months for those who received salvage chemotherapy.

Study details: ADMIRAL was a phase 3 trial involving 371 patients with AML.

Disclosures: The study was funded by Astellas. The investigators reported financial relationships with AbbVie, Bayer, Takeda, and other companies.

Citation:

Perl A et al. EHA Congress, Abstract S876.